British company GlaxoSmithKline Inc. (GSK) today announced that it has signed an agreement with the Government of Canada to provide 10,000 doses of Sotrovimab, a COVID-19 monoclonal antibody therapy developed by GSK and Vir Biotechnology.
Sotrovimab (XevudyÂ®) is a fully human anti-SARS-CoV-2 monoclonal antibody selected for its potential to neutralize beta-coronavirus in vitro, kill infected cells, provide a high barrier to resistance and achieve high concentrations in the lungs.
The agreement will allow provincial and territorial health systems to access sotrovimab starting in October 2021. The agreement includes the option for the Government of Canada to purchase additional doses in 2022 based on emerging needs.
Previously, Health Canada had granted authorization for Sotrovimab for injection on July 30, 2021.
Under its Interim Order Concerning the Importation, Sale and Advertising of Medicines for Use in Connection with COVID-19 for the Treatment of Mild to Moderate COVID-19, Confirmed by Direct SARS-Viral Testing VOC-2, in adults and adolescents (12 years of age and over weighing 40 kg or more) who are at high risk of progressing to hospitalization and / or death.
âWith the emergence of worrying variants across the country, particularly the Delta variant, new therapies like sotrovimab are important for treating the disease in its early stages,â said Ranya El Masri, head of government affairs and the market access for GSK Canada, in a press release.
âGSK is proud to partner with the Government of Canada to help Canadians gain access to sotrovimab, especially those who will benefit the most from this treatment, such as the elderly and those with certain chronic conditions that may put them at risk. a higher risk of hospitalization or death from COVID-19. ”
Sotrovimab is included in the US NIH COVID-19 treatment guidelines. COVID-19 Treatment Guidelines Expert Panel recommends the use of anti-SARS-CoV-2 monoclonal antibodies to treat mild to moderate COVID-19 and for post-exposure prophylaxis of SARS infection -CoV-2 in people at high risk of progression to severe COVID-19. 19, as stated in the US Food and Drug Administration.
Please see the Product Monograph at www.gsk.ca for complete safety information. For more information, please visit www.ca.gsk.com.